HGH Injections For Sale

DUBLIN--(BUSINESS WIRE)--The "Global Metabolic Partnering 2015-2022: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Global Metabolic Partnering 2015 to 2022 provides the full collection of 1100+ Metabolic disease deals signed between the world's pharmaceutical and biotechnology companies since 2015.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Metabolic disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Metabolic deals.

The report presents financial deal terms values for Metabolic deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Metabolic dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Metabolic dealmaking since 2015 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Metabolic deals since 2015. Deals are listed by headline value. The chapter includes the top 25 most active Metabolic dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Metabolic deals since 2015 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Metabolic partnering deals by specific Metabolic target announced since 2015. The chapter is organized by specific Metabolic therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Metabolic partnering deals signed and announced since 2015. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report includes deals for the following indications: Acromegaly, Addison's disease, Cirrhosis, Cushing's syndrome, Diabetes, Type 1, Type 2, Insipidus, Fatty liver, Gallstones, Goitre, Growth hormone disorders, Gynaecomastia, Inborn errors of metabolism, Phenylketonuria, Hyperaldosteronism, Hypercalcaemia, Hyperthyroidism, Hypocalcaemia, Hypogonadism, Hypopituitarism, Hypothyroidism, Liver disease, Nonalcoholic steatohepatitis (NASH), Lysosomal storage disorders, Nutrition and vitamins, Rickets, Pheochromocytoma, Primary bilary cirrhosis, Prolactinemia, Short stature, Syndrome of Inappropriate Antidiuretic Hormone (SIADH), Thyroid disease, plus other metabolic indications.

Report scope

Global Metabolic Partnering 2015 to 2022 includes:

In Global Metabolic Partnering 2015 to 2022, available deals and contracts are listed by:

Analyzing actual contract agreements allows assessment of the following:

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Metabolic dealmaking

2.1. Introduction

2.2. Metabolic partnering over the years

2.3. Metabolic partnering by deal type

2.4. Metabolic partnering by industry sector

2.5. Metabolic partnering by stage of development

2.6. Metabolic partnering by technology type

2.7. Metabolic partnering by therapeutic indication

Chapter 3 - Financial deal terms for Metabolic partnering

3.1. Introduction

3.2. Disclosed financials terms for Metabolic partnering

3.3. Metabolic partnering headline values

3.4. Metabolic deal upfront payments

3.5. Metabolic deal milestone payments

3.6. Metabolic royalty rates

Chapter 4 - Leading Metabolic deals and dealmakers

4.1. Introduction

4.2. Most active in Metabolic partnering

4.3. List of most active dealmakers in Metabolic

4.4. Top Metabolic deals by value

Chapter 5 - Metabolic contract document directory

5.1. Introduction

5.2. Metabolic partnering deals where contract document available

Chapter 6 - Metabolic dealmaking by therapeutic target

6.1. Introduction

6.2. Deals by Metabolic therapeutic target

Appendices

Appendix 1 - Directory of Metabolic deals by company A-Z since 2015

Appendix 2 - Directory of Metabolic deals by deal type since 2015

Appendix 3 - Directory of Metabolic deals by stage of development since 2015

Appendix 4 - Directory of Metabolic deals by technology type since 2015

For more information about this report visit https://www.researchandmarkets.com/r/7b8gbu

See more here:

Global Metabolic Partnering Report 2022: Deal Trends, Players and Financials Analysis of 1100+ Deals Signed Since 2015 - ResearchAndMarkets.com -...

SEOUL, South Korea--(BUSINESS WIRE)--Genexine (KOSDAQ: 095700), a publicly traded, clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, today announced the dosing of the first patient in phase 2 clinical trial using triple combination therapy in patients with recurrent/metastatic HNSCC. The combination therapy consists of two of Genexines proprietary drugs, GX-188E (a first-in-class therapeutic DNA vaccine), GX-I7 (a first-in-class long-acting interleukin 7), and OpdivoR (nivolumab), a marketed PD-1 immune checkpoint inhibitor.

The phase 2 clinical trial is being conducted in South Korea under the leadership of Professor Hye-Ryun Kim of the Department of Oncology at Yonsei Severance Hospital Cancer Center. The trial will evaluate the safety and efficacy in 21 patients with HPV-16 or 18-positive recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Endpoints assessed during the study include those related to safety and efficacy, including the overall rate of response.

I am very pleased to be leading this study with such a unique approach of combining a DNA vaccine, a long-acting Il-7 T-cell amplifier and a proven checkpoint inhibitor, said Professor Hye-Ryun Kim. Based on the potential synergy of the mechanisms of action of the three therapies, we could expect that the overall response rate in this patient population will be further enhanced versus the standard of care. The unmet medical need in HNSCC patients is substantial, so this landmark study will be an important milestone for these patients.

This study is very important for Genexine as it represents a unique approach to treating a very complicated and difficult cancer, said Neil Warma, President and CEO of Genexine. We are running separate trials with GX-188E in cervical cancer and GX-I7 in triple-negative breast cancer and glioblastoma, but the idea to combine both with a checkpoint inhibitor in HNSCC could challenge the standard of care and truly provide an important alternative for these patients and possibly to numerous other HPV related cancers.

Recurrent/metastatic head and neck squamous cell carcinoma is considered an incurable disease with a very poor prognosis and limited treatment options. It requires active treatments from the early stages. Since tumor cells develop in the oropharyngeal region, it significantly impacts patients lives, causing functional disability and a high mortality rate.

According to the National Institute of Health (NIH), around 70% of oropharyngeal cancer which takes a major portion of head and neck cancers in the United States are caused by human papillomavirus (HPV) infection. In addition, the unmet medical needs for HPV-positive head and neck cancer are very high due to the increasing incidence rate around the world.

Genexines proprietary immuno-oncology drug GX-I7 is being developed globally as a first-in-class drug. It amplifies absolute lymphocyte counts, therefore, increasing the number of T cells and has a mechanism to penetrate them into the tumor microenvironment. Another innovative drug being used in the triple combination is GX-188E. It is an anticancer DNA vaccine and has a mechanism of preferentially targeting HPV antigens to dendritic cells. Therefore, it is expected that the triple combination of the two novel pipelines with PD-1 immune checkpoint inhibitor OpdivoR will be an effective treatment strategy for HPV-positive head and neck cancer patients.

About Genexine

Genexine, Inc. is a publicly traded, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics. Primary technology platforms are Therapeutic DNA vaccine technology and hyFcR fusion technology. The company has multiple products in clinical development, including several undergoing Phase 3 registration trials. The company's proprietary pipeline includes GX-188E for cervical cancer and head and neck cancer, GX-I7 (efineptakin alfa) for multiple cancers, GX-H9 (eftansomatropin alfa) for Growth Hormone Deficiency and GX-E4 for CKD-induced anemia, among others. Genexine has established multiple partnerships with global companies in order to expedite product development and commercialization and create significant value. Genexine is listed on the Korean stock exchange (KOSDAQ: 095700) and is headquartered in Seoul, Korea. Genexine is committed to the well-being and care of patients worldwide.

Forward Looking Statements

This press release contains forward-looking statements regarding the business of Genexine, Inc. ("Genexine"). Any statement describing Genexine's goals, expectations, financial or other projections, intentions or beliefs, development plans and the commercial potential of Genexine's drug development pipeline, including without limitation GX-I7 (efineptakin alfa), GX-188E, GX-H9 (eftansomatropin alfa), GX- E4 is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to risks and uncertainties, particularly those challenges inherent in the process of discovering, developing and commercialization of new drug products that are safe and effective for use as human therapeutics and in the endeavor of building a business around such drugs.

Genexine's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Genexine's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Genexine. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Genexine's programs are described in additional detail in Genexine's annual reports on DART (Data Analysis, Retrieval and Transfer System) internet site (https://dart.fss.or.kr/ ) of the Korean Financial Services Commission. Genexine assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Link:

Genexine Announces Dosing of First Patient in Phase 2 clinical trial with Triple Combination Therapy in Patients with Head and Neck Squamous Cell...

Among the many moving targets to keep an eye on this season is off-target dicamba injury in soybeans. And its already evident in Midwestern states.

According to Prashant Jha, professor and Extension weed specialist at Iowa State University (ISU), ISU Extension field agronomists, commercial agronomists, and others across Iowa have observed non-dicamba tolerant soybean showing injury symptoms in line with dicamba.

As long as we have dicamba, it's not a question of if we ever will see off-target injury in a year, the only unknown is how extensive it will be, says Aaron Hager, associate professor and faculty Extension specialist at the University of Illinois Urbana-Champaign.

In Illinois, dicamba-related complaints peaked in 2019 at over 700. This summer, there are reports of widespread damage to soybeans in southern Illinois and complaints of pesticide misuse that specifically mention damage to trees. The signs are cupping in soybean leaves and bare trees in July and August.

Hager says that with a significant switch away from dicamba technology to Enlist technology this spring, many were hopeful for less off-target response.

Aaron Hager

The amount of dicamba sprayed in soybeans was less, but on the flip side, a higher percentage of acres are now sensitive to off-target movements, he says. When there is widespread use of a volatile product like dicamba at times of the growing season where temperatures are much higher than normal, we continue to see the effects across the landscape.

Gil Gullickson

Dicamba injury in soybeans.

Unfortunately, managing off-target movement is beyond a farmers control.

But the question if there is anything you can do to recover from damage has been asked before.

Brian Dintlemann, M.S. student, and Kevin Bradley, professor of plant science and technology at the University of Missouri, conducted a research trial over three seasons to determine if there may be any treatment for dicamba-injured soybeans.

The recovery treatments they tested included common foliar fertilizer products (PercPlus, Megafol, YieldOn, etc), a fungicide (Priaxor), urea with Agrotain, a plant growth hormone (Radiate), and weekly irrigation.

In their research, published in 2021, weekly irrigation was the only recovery treatment that resulted in yields that were higher than the dicamba-injured control. However, none of the recovery treatments resulted in yields that were as high as the non-treated control.

Results from all three years of the study indicate that if your soybeans have become injured with dicamba, the best thing to do is to irrigate. This will help them recover some, but not all.

In alignment with this research, Prashant Jha at ISU says that in areas of the state that have received rain, affected soybean plants with low levels of dicamba exposure are likely to outgrow the injury.

Prashant Jha

However, injury from dicamba drift is an ongoing concern and jeopardizes the use of this product as one of the few postemergence herbicide options left for controlling waterhemp in dicamba-tolerant soybean. Enlist One or glufosinate are also effective on waterhemp when applied over-the-top in Enlist E3 soybean, Jha notes.

University of Missouri Extension horticulturist Michele Warmund says there are few short-term solutions to prevent herbicide drift, but a long-term option is to plant protective structures, like a living windbreak.

Sorghum-Sudan grass is an annual plant that grows 5-12 feet tall. Multiple rows can provide an inexpensive annual barrier to protect low-growing crops against herbicide drift, according to Warmund.

Another option is a windbreak with multiple rows of perennial trees and shrubs. In a three-row windbreak, for example, one row of evergreen trees, a second row of shrubs, and a third staggered row of shrubs in a planting about 40-50 feet wide, will provide greater protection against herbicide drift than one with fewer rows.

However, even a single row of tall plants with dense foliage will help minimize damage, she says. You might consider American plum, silky or red twig dogwood, witch hazel, ninebark, and American filbert.

While there may be continued concern over off-target movement, weed control and resistance is at the top of the list for farmers too.

Dicamba is an important tool, especially right now, when growers need access to safe and effective crop protection, says Kyel Richards, Bayer Crop Science.

If you have experienced a suspected herbicide incident, contact your states Department of Agriculture or call the Bayer hotline number at 1-844-RRXTEND to report off-target movement or suspected resistance issues.

View original post here:

Evidence of off-target movement of dicamba in the Midwest - Successful Farming

Earth, a veteran planet known more for its craftiness than the quickness and explosiveness of its youth, put on a vintage performance earlier this summer, completing its fastest rotation on record. All the haters and doubters who counted Earth out are sobbing right now, absolutely sobbing.

On June 29, Earth spun through a full rotation in 1.59 milliseconds short of the league-average 24 hours, a breathtaking athletic feat witnessed by an estimated 7.97billion viewers. This sets a record for the fastest rotation of Earth since they started tracking the stat in 1955 with the advent of the first practical atomic clock. But as we all know, athletes are only getting stronger and faster; back then Earth was competing with a bunch of plumbers and mailmen.

The world record was verified by the International Earth Rotation and Reference Systems Service, the governing body for the passage of time itself, and first reported by Timeanddate, the go-to fan blog for time news, time scores, and time trade rumors. As Timeanddate notes, Junes record-setting performance didnt come in a vacuum. Well, it came in the vacuum of space, but you know what I mean; Earth has been enjoying a late-career resurgence. Though Earth has generally been rotating slower since its rookie year (about three milliseconds per day per century; thus the length of a day in the late Cretaceous would have been about 23 hours and 30 minutes), the last few seasons have seen Earth spinning increasingly faster.

The reasons for Earths comeback-player-of-the-year performance arent clear. Some credit a new training regimen; others a new offseason diet. Still others speculate a change in play-calling philosophy from Earths coach, the Sun, more suited to Earths abilities. Earth has also been dogged by whispers of PGH (planetary growth hormone) usage, though its possible those rumors were planted by its closest rivals, Mars and Venus. Its certainly odd, said Professor Matt King of the University of Tasmania. Clearly something has changed.

Scientists, who are basically sabermetrics nerds, have a number of theories, and one of the most popular is glacial isostatic adjustment. In this scenario, climate change is melting ice caps and thereby reducing the weight on Earths poles, allowing the Earth, which is wider than it is tall, to decompress into a shape a little closer to a sphere. Like a figure skater drawing their arms in, this would allow the Earth to spin faster.

Another theory involves the Chandler Wobble, which is the periodic wandering of the center of rotation. Over the last couple of yearsprobably driven by changes in ocean circulationthe wobble has been at a historic minimum; the Earth has been more like a football thrown in a tight spiral than a Peyton Manningesque wounded duck.

Given that changes in both of those things can be linked to mass moving around on the surface of the Earth, its probably not a bad guess that those things are linked in some way, King said. I dont know if we are very much further along the lines of understanding whats going on, but I dare say theresprobably something going on in the climate system or in the oceans.

Whatever the reason or reasons, Earths recent performance has been so impressive that theyre considering changing the rules of the sport. A few more years of sub-24-hour times and we will need the first-ever negative leap secondthe skipping of one second in the International Atomic Time, the official global time, in order to bring it back into alignment with the Earths rotation. Sure, Barry Bonds hit a bunch of dingers and set a bunch of records. But did he force us to literally jump forward in time? Earth is the greatest to ever do it.

Follow this link:

Earth, The True GOAT, Breaks Longstanding Speed Record - Defector

image:Rachel Kratofil view more

Credit: Rachel Kratofil

University of Calgary researchershave identified a promising new approach to treating bacterial skin infections.In astudy recently published inNature,first author Dr. Rachel Kratofil, PhD, and co-senior authors Drs. Paul Kubes, PhD, Justin Deniset, PhD, and their research team show new insight which could lead to advancements in treating bacterial infections and wounds.

While translating our research from bench to bedside will require many more experiments and involve a model more closely related to human disease, it is exciting that we have made a fundamental discovery that could improve infections and tissue repair in humans, especially hard-to-treat cases, says Kratofil.

Traditionally, researchers have thought that both neutrophils and monocytes (white blood cells) were recruited to clear bacteria from an infected site on the skin. When these cells work together, they act as the immune systems first line of defense in our bodies.

However, the new research reveals that monocytes alone are capable of facilitating faster healing of wounds. Monocytes help the healing process by regulating leptin levels and blood vessel growth during wound repair. They also produce ghrelin, a hormone that helps wounds heal more efficiently.

Surprising connection between metabolic hormones and tissue repair

Ghrelin is produced by the stomach when you are hungry, and leptin also a hormone is produced by fat cells after you eat a meal and feel full. This balance between ghrelin and leptin has long been understood as critical to metabolism and diet, but until now, has not been known for its connection to immune mechanisms and tissue repair.

Using intravital microscopy, which allows observation of live cells and is a specialization of the Kubes Lab, Kratofil was able to visualize the immune response toStaphylococcus aureus(S. aureus)bacteria in an animal model.

S. aureusis a germ commonly found on skin or in the nose of a healthy body. It can be a catalyst for a wide variety of diseases related to skin and tissue infections such as abscesses or boils. In some cases, the bacteria can lead to severe infections like pneumonia and endocarditis,a life-threatening inflammation of the inner lining of the heart's chambers and valves.

After anS. aureusinfection, the body recruits those helpful immune cells, neutrophils and monocytes. Neutrophils clear bacteria, while monocytes help repair tissue. In the absence of monocytes there is increased leptin production, leading to blood vessel growth in the infection. The result can be delayed healing and scarring. In contrast, monocytes produce ghrelin at the infection site, which blocks the formation of excess blood vessel growth driven by leptin, leading to tissue repair.

Importance of the studys results

This research is important because it indicates a paradigm shift challenging the current thinking that neutrophils and monocytes clear bacteria. Our study elevates the role of monocytes in wound repair, explains Kratofil.

Principal investigator Kubes and his research team believe this study opens the door to introduce metabolic hormones (ghrelin and leptin) in the fields of immunology and microbiology.

It will be interesting, for example, to see how ghrelin and leptin respond in other disease models such as sterile injury or cancer, and to learn how these processes are altered when a patient has multiple simultaneous diseases or conditions such as obesity and diabetes, says Kubes.

Next steps

The next step for the researchers is to better understandthe functions of immune cells such as neutrophils during infection. Specifically, they are interested in how neutrophils become cleared from an infection and whether neutrophils take on different functions in addition to clearing bacteria.

This research teams interdisciplinary work is the product of 133 independent experiments that were carried out in collaboration with the labs of Dr. Keith Sharkey, PhD (Snyder Institute, Hotchkiss Brain Institute (HBI)), Dr. Jeff Biernaskie, PhD, (HBI and Alberta Childrens Hospital Research Institute), and researchers from University Hospital Regensburg, Germany, and Texas A&M University.

Funding for this study was provided by the Canadian Institutes of Health Research.

Experimental study

Animals

A monocyteleptinangiogenesis pathway critical for repair post-infection

29-Jun-2022

The authors declare no competing interests.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read more from the original source:

Snyder Institute researchers discover new approach to healing skin infections and wounds - EurekAlert

Acne is a persistent skin inflammation problem which most commonly affects the face, sometimes the shoulders, back, neck, chest, or upper arms too and results in patches and pimples. Although it can happen at any age, it frequently happens during puberty when the sebaceous glands are active. Although it is not harmful, it may leave skin scars. Acne can be caused due to multiple reasons such asexcessive production of oil (sebum), blocked hair follicles from oil and skin cells infection caused by bacteria. According to various studies, eating certain foods may exasperate acne. What are these worst foods for acne?

Following a particular dietary limitation can work in favour of those battling acne. Simrun Chopra, a well-known nutritionist and deep health coach, shared some dietary suggestions that can help you fight acne problems.

Check out her Instagram post!

A diet that excludes eating anything with gluten is known as a gluten-free diet. A gluten-free diet can help you prevent acne if your skin is gluten-sensitive. Barley, rye, triticale and wheat contain gluten and so you have to avoid eating these grains. Some natural gluten-free items include vegetables and fruit, natural and unprocessed forms of beans, seeds, legumes and nuts, eggs and non-processed meats, seafood, and poultry. You can even ask your dietician to make a gluten-free diet routine for you.

Artificial hormones are given to dairy cows, which affects how much milk they produce. According to researchers, consuming milk products may cause those hormones to disturb your hormone balance. This might result in acne.As per another hypothesis, acne will always be made worse by the growth hormones included in milk. Thus, having dairy product can worsen the situation if you have acne.

Large fatty acid intakes, like those found in an average Indian diet, are connected to higher rates of inflammation and acne. This may be due to the high levels of oils in the diet which are high in omega-6 fatty acids. This overabundance of fatty acids causes the body to become inflammatory, which may make acne worse.

Watch your acne for a week, and see if you find a difference after avoiding these foods. If you do, then you need to do an elimination protocol to see which of the three was the culprit and what do you need to remove and what to add back. For most people, these three in moderation usually works, Chopra says.

Chopra recommends a teaspoon of a good seed mix which can give you a dose of vitamins and good fats.

Omega-3 fatty acids are a nutrient that can aid with acne treatment and are found in foods like fish oil, wild salmon, nuts, and seeds. A great source of omega-3 fatty acids is fish oil. Fatty acids can help with general skin health as well as specific skin issues like eczema and acne.

Water aids in the removal of toxins and bacteria from the skin when treating bacterial acne, hence lowering the risk of pore clogging. It also helps in maintaining good skin by keeping it moisturized and promotes collagen formation and skin cell renewal.

Yellow and orange fruits and vegetables can be good for acne because of their antioxidant and anti-inflammatory properties. It is advised to have more yellow and orange fruits and vegetables such as carrots, apricots, and sweet potatoes etc.

See original here:

Make these changes to your diet to say goodbye to acne - Health shots